Metraipolis › archive › dc_eb23ee522be1

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the… — Europe PMC PMID:41841331

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41841331
DOI: 10.1111/iju.70400
License (as archived): solo-consultazione
Archived: 2026-11-05T11:55:46.843Z
SHA-256 of the archived text: c3a4bd68bc25254f2589134e36d4aa6da33d624543671143b244ec9ed9157171
Stable URL of this page: https://metraipolis.com/documento/dc_eb23ee522be1

How to cite

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the… — Europe PMC PMID:41841331 — Europe PMC (en), https://europepmc.org/article/MED/41841331 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eb23ee522be1 (Metraipolis archive dc_eb23ee522be1, sha256 c3a4bd68bc25254f2589134e36d4aa6da33d624543671143b244ec9ed9157171)

BibTeX

@misc{dceb23ee522be1,
  title = {A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the… — Europe PMC PMID:41841331},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41841331},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eb23ee522be1; sha256 c3a4bd68bc25254f2589134e36d4aa6da33d624543671143b244ec9ed9157171},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41841331. Agents can read the archived copy with the MCP tool read_document.